TransMedics (TMDX) Capital Expenditures (2018 - 2026)

TransMedics' Capital Expenditures history runs 9 years deep, the most recent figure standing at $36.7 million for Q1 2026.

• On a quarterly basis, Capital Expenditures rose 35.58% year-over-year to $36.7 million in Q1 2026; TTM through Mar 2026 was $68.9 million, a 505.48% increase from a year earlier, with the FY2025 full-year figure at $59.3 million, up 39665.77% from the prior year.
• Capital Expenditures rose to $36.7 million in Q1 2026 per TMDX's latest filing, from $15.5 million in the prior quarter.
• Across five years, Capital Expenditures topped out at $151.8 million in Q4 2023 and bottomed at -$116.0 million in Q4 2024.
• The 5-year median for Capital Expenditures is $2.8 million (2022), against an average of $15.3 million.
• Biggest YoY gain for Capital Expenditures was 683123.53% in 2024; the steepest drop was 5057.48% in 2024.
• Year by year, Capital Expenditures stood at $2.8 million in 2022, then surged by 5391.79% to $151.8 million in 2023, then slumped by 176.41% to -$116.0 million in 2024, then surged by 113.38% to $15.5 million in 2025, then jumped by 136.28% to $36.7 million in 2026.
• Per Business Quant, the three latest TMDX Capital Expenditures figures stand at $36.7 million (Q1 2026), $15.5 million (Q4 2025), and $43.7 million (Q3 2025).